Maravai LifeSciences Holdings Inc. Class A Common Stock vs National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares trades at $79.45 (market cap $78.99B). The key difference: National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares is far larger — about 80.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares pays a 4.13% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| MRVI | NGG | |
|---|---|---|
Market Cap | $977.37M | $78.99B |
Volume | 2,742,564 | 740,402 |
Sector | Health | Utilities |
52-Week High | $9.00 | $93.93 |
52-Week Low | $2.83 | $73.54 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $1.08B | $137.22B |
Dividend Yield | — | 4.13% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
National Grid (NGG) trades at $78.23, up 1.44% on the day, with a market cap of approximately $48.3 billion. The stock shows stable technicals near its consensus price target of $79.25. Fundamentally, it maintains strong profitability with an 18.32% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights institutional buying and a focus on grid innovation, including AI adoption.
Outlook is cautiously positive with upside to the high target of $85.50, supported by earnings momentum and strategic investments. Risks include high debt levels and regulatory pressures. Analyst consensus leans buy (55%), but hold ratings reflect concerns over capital intensity and macroeconomic sensitivity.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →National Grid plc is a British utility company that owns and operates electricity and gas transmission networks in Great Britain, and through its US Regulated business, operates electricity and gas transmission and distribution networks serving customers in New York and Massachusetts. Its shares trade on the NYSE as American Depositary Shares under the ticker NGG.
Read more on NGG →